Available-for-Sale Debt Securities - Unrealized Loss Position
Moderna Available-for-Sale Debt Securities - Unrealized Loss Position increased by 218.9% to $3.87B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.9%, from $3.13B to $3.87B. Over 4 years (FY 2021 to FY 2025), Available-for-Sale Debt Securities - Unrealized Loss Position shows a downward trend with a -40.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Higher values indicate increased exposure to interest rate hikes or credit risk within the investment portfolio.
Detailed definition
This metric identifies the portion of debt securities classified as available-for-sale that are currently trading below...
Peer comparison
Standard disclosure for companies with significant cash management or captive finance operations.
afs_debt_securities_unrealized_loss_positionHistorical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.35B | $13.00B | $14.16B | $13.52B | $13.16B | $11.12B | $10.55B | $9.16B | $8.01B | $8.77B | $8.26B | $4.47B | $4.32B | $3.13B | $2.56B | $1.37B | $1.21B | $3.87B |
| QoQ Change | — | +39.1% | +8.9% | -4.5% | -2.7% | -15.5% | -5.1% | -13.2% | -12.5% | +9.4% | -5.8% | -45.9% | -3.3% | -27.6% | -18.0% | -46.6% | -11.3% | +218.9% |
| YoY Change | — | — | — | — | +40.8% | -14.5% | -25.5% | -32.2% | -39.1% | -21.1% | -21.7% | -51.3% | -46.1% | -64.4% | -69.0% | -69.4% | -71.9% | +23.9% |
Available-for-Sale Debt Securities - Unrealized Loss Position at Other Companies
Frequently Asked Questions
- What is Moderna's available-for-sale debt securities - unrealized loss position?
- Moderna (MRNA) reported available-for-sale debt securities - unrealized loss position of $3.87B in Q1 2026.
- How has Moderna's available-for-sale debt securities - unrealized loss position changed year-over-year?
- Moderna's available-for-sale debt securities - unrealized loss position increased by 23.9% year-over-year, from $3.13B to $3.87B.
- What is the long-term trend for Moderna's available-for-sale debt securities - unrealized loss position?
- Over 4 years (2021 to 2025), Moderna's available-for-sale debt securities - unrealized loss position has grown at a -40.0% compound annual growth rate (CAGR), from $9.35B to $1.21B.
- What does available-for-sale debt securities - unrealized loss position mean?
- The value of debt investments currently worth less than what the company paid for them.